Abstract: There is a need for delivery platforms with robust capacity that offer the possibility to deliver diverse protein-based therapeutics into specific cells. Described herein is a platform for delivering cargo polypeptides into cells, which is based on a recombinant molecule comprising: a cargo polypeptide, a diphtheria toxin enzymatic fragment (DTA), and a diphtheria toxin translocation fragment (DTB). The platform has been employed to deliver diverse cargo into cells, including those having low or high molecular weights. A hyper-stable cargo polypeptide has been delivered, as well as proteins of therapeutic significance (e.g, MecP2, SMN, FMRP, PNP, alpha-amylase, and RRSP). The platform is also useful for delivering genome-modifying proteins, such as the CRISPR protein, Cas9. Associated nucleic acids, pharmaceutical compositions, methods, uses, and kits are also described, including those of therapeutic significance aimed at treating diseases or disorders caused by enzyme or protein deficiency.
Type:
Grant
Filed:
November 30, 2017
Date of Patent:
March 24, 2020
Assignee:
THE HOSPITAL FOR SICK CHILDREN
Inventors:
Roman A. Melnyk, Anick Auger, Greg Beilhartz, Berge Minassian, Seiji Sugiman-Marangos
Abstract: A method of diagnosing cancer in a mammal is provided. The method includes the steps of determining in a nucleic acid-containing sample from the mammal the degree of DNA methylation of a target region within the hTERT promoter from the nucleotide at about position ?157 to the nucleotide at about position ?580, or a corresponding target region in a TERT promoter in a mammal other than a human, to yield a sample methylation signature, determining the baseline degree of DNA methylation of the target region in a control sample to yield a control methylation signature, comparing the sample methylation signature to the control methylation signature and rendering a diagnosis of cancer when there is at least 1.5 times more methylation in the sample methylation signature as compared to the control methylation signature. Methods of determining tumour grade and progression, predicting survival and determining whether or not a mammal is a candidate for telomerase-targeted or demethylation therapy are also provided.
Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
Type:
Grant
Filed:
March 7, 2018
Date of Patent:
March 3, 2020
Assignees:
The Hospital For Sick Children, Centre for Addiction and Mental Health
Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
Type:
Grant
Filed:
March 7, 2018
Date of Patent:
March 3, 2020
Assignees:
The Hospital for Sick Children, Centre for Addiction and Mental Health
Abstract: A method for treating and/or preventing VacA+ H. pylori infection and a disorder associated with VacA+ H. pylori infection is provided. The method comprises the administration of TRPML agonists such as ML-SA1, SF-22, SF-51, MK6-83 and their derivatives.
Type:
Application
Filed:
April 6, 2017
Publication date:
January 16, 2020
Applicant:
The Hospital for Sick Children
Inventors:
Nicola JONES, Laura GREENFIELD, Mariana CAPURRO
Abstract: Methods of determining the risk of ASD in an individual are provided which comprise identifying the presence of one or more genomic mutations in one or more of the genes, PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1.
Type:
Grant
Filed:
February 24, 2015
Date of Patent:
January 7, 2020
Assignees:
The Centre for Addiction and Mental Health, The Hospital for Sick Children
Abstract: A method for treating an infection comprises administering a peptide in synergistic combination with an antibiotic, wherein the peptide comprises an amino acid sequence with a formula selected from the group consisting of: Bn1-Z;??(a) Bn1-Z-Bn2; and??(b) Z-Bn1??(c) wherein B is a basic amino acid residue; n1 and n2 are 1 to 6; and Z is a sequence of from about 7 to about 24 amino acid residues, said sequence having an average hydrophobicity value of at least 0.3 on the Liu-Deber scale.
Abstract: There is provided a system, methods and apparatuses for stopping the development of paroxysms based on a feedback stimulation at low frequencies for a few seconds after the detection of a seizure precursor.
Type:
Grant
Filed:
June 9, 2016
Date of Patent:
October 29, 2019
Assignees:
THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO, THE HOSPITAL FOR SICK CHILDREN
Inventors:
Muhammad Tariqus Salam, Roman Genov, Jose Luis Perez-Velazquez
Abstract: A method of treating a medulloblastoma in a mammal is provided comprising administering to the mammal a compound having the following general formula (1): wherein X is selected from the group consisting of hydrogen, hydroxyl (—OH), halogen, thio (—SH), sulfanyl (—SR), sulfinyl (—SOR), sulfonyl (—SO2R), carboxyl (—COOH), carbonyl (COOR), nitro (—NO2), nitroso (—NOR), amino (NH2), NHR, NRR1, cyano (—CN) and isocyano (—NC), wherein R and R1 are independently C1-C5 branched or unbranched lower alkyl; and Y is a 5- or 6-membered unsaturated ring, optionally substituted, or a pharmaceutically acceptable salt thereof.
Abstract: This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.
Type:
Grant
Filed:
February 8, 2013
Date of Patent:
September 10, 2019
Assignees:
THE HOSPITAL FOR SICK CHILDREN, POPULATION BIO, INC.
Inventors:
Eli Hatchwell, Peggy S. Eis, Stephen Scherer, Aparna Prasad
Abstract: The invention provides methods for reducing the incidence and/or severity and/or delaying the onset of heart dysfunction/failure and improving overall survival through the use of remote ischemic per-conditioning and post-conditioning.
Abstract: Embodiments herein include variants of ?-hexosaminidase that are useful for hydrolyzing GM2 ganglioside, polynucleotides encoding the same, and related methods. In various embodiments, a variant ?-hexosaminidase subunit is included wherein the variant ?-hexosaminidase subunit forms a homodimer under physiological conditions and wherein the variant ?-hexosaminidase subunit associates with GM2 activator protein to hydrolyze GM2 ganglioside. In some embodiments, an isolated or recombinant polynucleotide encoding such a variant ?-hexosaminidase subunit is included. In some embodiments, a method of treating a subject exhibiting an abnormal cellular accumulation of GM2 ganglioside is included wherein the method includes administering a composition including a protein variant of ?-hexosaminidase or a polynucleotide encoding the same. Other embodiments are included herein.
Type:
Grant
Filed:
March 17, 2015
Date of Patent:
September 3, 2019
Assignees:
The University of Manitoba, The Hospital for Sick Children
Abstract: The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a sample of a subject by detecting oncogenic and cancer related proteins in microvesicles, and to the use of an agent blocking exchange of microvesicles for treating cancer.
Type:
Grant
Filed:
January 12, 2015
Date of Patent:
July 16, 2019
Assignees:
THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY, THE HOSPITAL FOR SICK CHILDREN
Inventors:
Janusz Rak, Khalid Al-Nedawi, Brian Meehan, Abhijit Guha
Abstract: The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a sample of a subject by detecting oncogenic proteins in microvesicles, and to the use of an agent blocking exchange of microvesicles for treating cancer.
Type:
Grant
Filed:
October 29, 2015
Date of Patent:
June 11, 2019
Assignees:
THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY, THE HOSPITAL FOR SICK CHILDREN
Inventors:
Janusz Rak, Khalid Al-Nedawi, Brian Meehan, Abhijit Guha
Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
Type:
Application
Filed:
November 27, 2018
Publication date:
May 23, 2019
Applicants:
HUMAN MATRIX SCIENCES, LLC, THE HOSPITAL FOR SICK CHILDREN
Inventors:
Felipe Jimenez, Thomas Mitts, Aleksander Hinek
Abstract: The invention contemplates, inter alia, the use of remote ischemic conditioning in the treatment of cancer, neurodegenerative disorders, and gastrointestinal disorders, among others.
Abstract: This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.
Type:
Grant
Filed:
September 27, 2013
Date of Patent:
March 19, 2019
Assignees:
THE HOSPITAL FOR SICK CHILDREN, POPULATION BIO, INC.
Inventors:
Eli Hatchwell, Peggy S. Eis, Stephen Scherer, Aparna Prasad
Abstract: This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.